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Background-—Small artery pathophysiology is frequently invoked as a cause of obesity-related diastolic heart failure. However,
evidence to support this hypothesis is scant, particularly in humans.
Methods and Results-—To address this, we studied human small artery structure and function in obesity and looked for
correlations between vascular parameters and diastolic function. Seventeen obese patients with metabolic syndrome and 5 control
participants underwent echocardiography and subcutaneous gluteal fat biopsy. Small arteries were isolated from the biopsy and
pressure myography was used to study endothelial function and wall structure. In comparison with the control group, small arteries
from obese participants exhibited significant endothelial dysfunction, assessed as the vasodilatory response to acetylcholine and
also pathological growth of the wall. For the obese participants, multiple regression analysis revealed an association between left
atrial volume and both the small artery wall thickness (b=0.718, P=0.02) and wall-to-lumen ratio (b=0.605, P=0.02). Furthermore,
the E:E0 ratio was associated with wall-to-lumen ratio (b=0.596, P=0.02) and inversely associated with interleukin-6 (b=0.868,
P=0.03). By contrast, endothelial function did not correlate with any of the echocardiographic parameters studied.
Conclusions-—Although the small arteries studied were not cardiac in origin, our results support a role for small artery remodeling
in the development of diastolic dysfunction in humans. Further direct examination of the structure and function of the myocardial
resistance vasculature is now warranted, to elucidate the temporal association between metabolic risk factors, small artery injury,
and diastolic impairment. ( J Am Heart Assoc. 2017;6:e004603. DOI: 10.1161/JAHA.116.004603.)
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H eart failure describes a clinical spectrum with anumber of different etiologies. Traditionally, although
the clinical focus has been on heart failure associated with
reduced left ventricular ejection fraction, a second category
of heart failure is recognized, in which systolic function is
preserved but symptoms and complications still occur. The
natural history of heart failure with preserved ejection
fraction (HFpEF) describes a preclinical phase, in which
there is diastolic dysfunction in the absence of symptoms.1
Imaging studies with echocardiography at this early stage of
disease (Grade I or Ia) reveal characteristic patterns of
impaired diastolic relaxation, with or without mild evidence
of increased filling pressures. The reduction in left ventricular
(LV) compliance leading to diastolic dysfunction causes
progressive change in atrial morphology and function that
represent early surrogate markers for HFpEF. Although our
understanding of the causes of HFpEF is some years behind
heart failure with reduced ejection fraction, epidemiological
studies have shown that there are disproportionately high
rates of diabetes mellitus, hypertension, and obesity in these
patients.2,3 This has become an area of intense interest, and
a number of conceptual models have been proposed to
explain the connection between these risk factors and the
development of symptomatic heart failure.4 One such model
is that microvascular disease underpins changes to the
myocardium seen in HFpEF, through inflammatory and redox
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pathways.5 When considering the profound effect that these
same cardiovascular6 and metabolic risk7 factors have on
small artery structure and function,8 and consequently the
prognostic relevance of these changes to target organ
damage,9 positioning resistance vessels at the center of any
mechanistic framework in HFpEF seems justified. However,
there are currently no studies that have explored the
relationship between small resistance arteries and the heart
in the setting of human obesity. In contrast to the paucity of
small artery studies, large artery-to-heart studies have
yielded many valuable insights into the vascular origins of
myocardial dysfunction,10 correlating aortic pulse wave
velocity with left atrial remodeling in hypertensive patients11
or demonstrating an association between reductions in
arterial compliance and progressively abnormal diastolic
function in hypertensive patients with exertional dyspnea.12
Pathological small artery remodeling frequently precedes
larger artery dysfunction and target organ damage. Further-
more, metabolic disease, especially diabetes mellitus and
obesity, influences growth of the small artery wall in
response to elevated blood pressures.8,13 Thus, we hypoth-
esized that alterations in small artery wall-to-lumen ratio and
arterial wall hypertrophy would correlate with left atrial
remodeling and diastolic impairment in patients with
metabolic syndrome. We investigated this by performing
echocardiography in patients with obesity and metabolic
syndrome and pairing this with small artery structural and
functional profiling of subcutaneous small arteries.
Methods
Study Population
Seventeen participants with National Cholesterol Education
Program Adult Treatment Panel III defined metabolic syn-
drome14 and 5 control participants were recruited from a
general medicine clinic and a day case programmed
investigation unit at Manchester Royal Infirmary. All partic-
ipants gave full written informed consent for the study,
which was approved by the Local Research Ethics Commit-
tee. On the day of study, fasting venous blood samples were
taken to assess renal function, glucose, and lipid profile in
addition to the inflammatory markers: high-sensitivity C-
reactive protein,tumor necrosis factor-a (TNF-a), and inter-
leukin-6 (IL-6). Blood pressure was measured with subjects
sitting, after 15 minutes of rest, by a semiautomatic
machine (OMRON 705 CP, White Medical) with a mean of
3 readings recorded. Anthropometric measurements were
also taken. Apart from hypertension or abnormalities of lipid
metabolism, patients were excluded if diagnosed with
chronic disease (eg, diabetes mellitus, heart, renal, or
inflammatory disease).
Definition of Metabolic Syndrome and Insulin
Resistance
The 2001 National Cholesterol Education Program Adult
Treatment Panel III was used to classify patients for this
study. The metabolic syndrome was defined as 3 or more of
the following characteristics: central obesity as measured by a
waist circumference >102 cm in men or 88 cm in women,
triglycerides >1.7 mmol/L, high-density lipoprotein choles-
terol (<1.03 mmol/L in men or <1.29 mmol/L in women),
fasting blood glucose >6.1 mmol/L, and hypertension (sys-
tolic >130 mm Hg or diastolic >85 mm Hg, or current use of
antihypertensive drugs).14,15
Pressure Myography
A single subcutaneous gluteal fat biopsy was obtained from
each subject by using 3 to 5 mL of 2% lignocaine, allowing
tissue (291.591.5 cm) to be harvested and placed immedi-
ately in ice-cold physiological saline solution (PSS). Small
arteries 100 to 150 lm in diameter were dissected from the
tissue and carefully cleaned under a dissecting microscope.
Isolated vessels were then transferred to an arteriographic
bath chamber (Living Systems Instrumentation) and cannu-
lated as described previously.16
The chamber was placed on the stage of an inverted
microscope and superfused with PSS, gassed with 5% CO2/
95% air (pH 7.4–7.45) at 37°C, at a superfusion rate of
20 mL/min. PSS composition was (mmol/L) 139 NaCl, 4.7
KCl, 25 NaHCO3, 1.17 KH2PO4, 1.17 MgSO4, 0.026 EDTA,
1.6 CaCl2, and 5.5 glucose. Lumen diameter was recorded
with the use of a Video Dimension Analyser (Living Systems
Instrumentations) connected to a chart recorder. Vessels
were connected to a pressure servo system (Living Systems
Instrumentation) and pressurized to 60 mm Hg; any vessel
with a leak was discarded. Vessels were allowed to
equilibrate to 37°C for 1 hour and then challenged with




After viability assessment with KPSS, each vessel was
stimulated as follows: (1) Cumulative addition of nore-
pinephrine (Sigma-Aldrich), 109, 39109, 108, 39108,
107, 39107, 106, 39106, 105 mol/L with 3 to
5 minutes incubation per concentration. (2) Endothelial
function was assessed via the cumulative response to
acetylcholine (Sigma-Aldrich) achieved by adding serial con-
centrations (mol/L) 109, 39109, 108, 39108, 107,
39107, 106, 39106, 105 to a preconstricted vessel with
105 norepinephrine. After 1 hour of incubation with
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59105 mol/L NG-monomethyl-L-arginine (Sigma), a NO
synthase inhibitor, the responses to acetylcholine were
repeated as in step 2 above.
Pressure Myography: Passive Structure
Measurement
The vessel was superfused for 20 minutes with Ca-free PSS
containing 2 mmol/L ethylene glycol-bis (-amino ethyl
ether)-N,N,N1,N1-tetraacetic acid to ensure the vessels were
devoid of active tone. To determine the structural properties
of the arteries, the intraluminal pressure was reduced to
3 mm Hg to determine the unstressed diameter and then
increased in steps to 20, 40, 60, 80, 100, 120, 140, 160,
and 180 mm Hg.
Calculations
The wall/lumen ratio was calculated as WT/D9100, where
WT is wall thickness and D is lumen diameter.
Wall cross-sectional area (CSA) was calculated as:
CSA ¼ pðDþ 2WT=2Þ2  pðD=2Þ2
Echocardiography
Echocardiographic studies were performed by a single operator
(ML) who was blinded to the patient status at the time of the
scan. Standard parasternal and apical imaging planes were
obtained with commercially available echocardiographic equip-
ment (Sonos 5500; Philips Medical Systems, Andover, MA).
Images were stored as digital loops to optical disc for later
analysis. Cardiac chamber quantification was performed
according to American Society of Echocardiography guide-
lines.17 Left atrial volume was calculated using the modified
Simpsons method in the 4- and 2-chamber apical views at end-
systole. Transmitral pulsed wave Doppler was used to obtain
early (E wave) and late (A wave) diastolic filling velocities and E/
A ratio as a marker of diastolic function. Myocardial perfor-
mance index was calculated as has been described previ-
ously.18 LV mass was calculated using the formula:
LV mass ðgÞ ¼ 0:8 ½1:04\ðLVEDDþ IVSdþ PWd[ 3
 LVEDD3Þ þ 0:6
Tissue Doppler parameters were measured using pulsed-
wave tissue Doppler imaging with the sampling cursor
positioned at the septal and lateral mitral valve annulus.
Early (E0) and late (A0) myocardial diastolic velocities were
measured and E/E0 ratio was calculated as a marker of left
atrial pressure.
Statistical Analysis
Data are expressed as meanSD. Comparison of charac-
teristics between groups were made using the Mann–
Whitney U test. Data for all diastolic parameters (mean
tissue Doppler imaging E:A, mean E:E0, mean E:A and 2-
chamber left atrial volume were transformed using log
base 10 to normalize skewed distributions. The indepen-
dent variables for this study were therefore CSA, wall
thickness, wall:lumen ratio, endothelial function, and high-
sensitivity C-reactive protein. Multivariable linear regres-
sion models were used to investigate the influence of the
independent variables on the variance of diastolic param-
eters. Stepwise model building was used to estimate the
relative contribution of each independent variable and the
variability of the diastolic parameters. All analyses were
adjusted for age and sex. Test collinearity diagnostics
indicated that CSA, wall thickness, and wall:lumen ratio
could be used in the same model. The unstandardized
(BSE) coefficients are the coefficients of the estimated
regression model. The standardized coefficients (b) are an
attempt to make the regression coefficients more com-
parable. The change in R2 (the coefficient of variations) is
the increased percentage of the variation explained when
each variable was added to the model. Statistical analysis
was performed using SPSS statistical software (version
21; SPSS, Chicago, IL).
Table 1. Demographic Details of Participants With Metabolic
Syndrome and Controls
Characteristics MetS (n=17) Controls (n=5) P Value
Age, y 54.411.2 49.612.3 0.45







Total cholesterol, mg/dL 169.438.1 249.611.4 0.002
HDL cholesterol, mg/dL 39.98.8 57.79.4 0.001
Total/HDL cholesterol ratio 4.41.1 4.40.6 1.00
Triglycerides, mg/dL 138.051.9 116.623.7 0.36
Fasting glucose, mg/dL 109.615.9 92.68.9 0.10
Heart rate, bpm 66.59.7 59.25.2 0.12
hsCRP, mg/L 5.145.26 1.440.66 0.10
Leptin, lg/L 29.5815.78 8.787.67 0.002
Baseline characteristics and differences between control subjects (n=5) and patients
with metabolic syndrome (n=17). Values are meanSD. HDL indicates high-density
lipoprotein; hsCRP, high-sensitivity C-reactive protein).
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A comparison of the demographic data between the metabolic
syndrome group and controls is given in Table 1. Those with
metabolic syndrome had significantly higher mean body mass
index and leptin. The mean level of high-density lipoprotein
cholesterol was significantly lower in the metabolic syndrome
group, while there was no significant difference in the mean
level of triglycerides between the 2 groups.
Echocardiography, Small Artery Structure and
Function in Metabolic Syndrome
Endothelial function (Figure 1A) was measured as average
maximal relaxation to acetylcholine. Those with metabolic
syndrome had significantly impaired endothelial function
compared with control participants (86.7411.60% versus
98.704.31%, P=0.004). This level of damage is consistent
with that seen in other clinical studies of small artery function
in obesity. Endothelial function ranged from normal (99.2% of
resting diameter after maximal acetylcholine concentrations)
to significantly impaired (59.6% of resting diameter) in the
metabolic syndrome group. Data were also collected on
acetylcholine relaxations after 1-hour incubation with a NOS
inhibitor (NG-monomethyl-L-arginine) and presented in the
dose–response curve in Figure 1B. Of the small artery
structural indices, mean wall thickness was significantly
greater in patients with metabolic syndrome compared with
control participants, consistent with previous studies. There
were no significant differences in cross-sectional area and
wall-to-lumen ratio of the small arteries between the 2 groups
(Table 2). There were no significant differences in left
ventricular ejection fraction between the control group and
A
B
Figure 1. Assessment of endothelial function in patients with metabolic syndrome and controls. A, Effect
of acetylcholine dilation on preconstricted small arteries from subcutaneous gluteal fat biopsy samples
from control participants and patients with metabolic syndrome measured in a pressurized system. B,
Acetylcholine relaxations after 1-hour incubation with L-NMMA in control participants and those with
metabolic syndrome. L-NMMA indicates NG-monomethyl-L-arginine.
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patients with metabolic syndrome; however, diastolic param-
eters were deranged: the mean E:A ratio was significantly
lower in the metabolic syndrome group (metabolic syndrome:
0.930.23 versus control participants: 1.190.17, P=0.048),
representing impaired relaxation and grade I diastolic dys-
function. There were no significant differences in the lateral E:
E0 ratio (8.904.17 in metabolic syndrome versus 5.731.68
in control participants, P=0.16). A value less than 8
corresponds with normal ventricular relaxation. LV mass
was similar in both groups.
Correlations Between Subcutaneous Small Artery
Structure and Function and Cardiac Parameters
in Patients With Metabolic Syndrome
As summarized in Table 3 and Figure 2, following adjustment
for age and sex, a statistically significant association was
found between 2-chamber left atrial volume and both wall
thickness (b=0.718, P=0.02) and wall-to-lumen ratio
(b=0.605, P=0.02). In addition, wall-to-lumen ratio was also
significantly associated with lateral E:E0 values (b=0.596,
P=0.02). A significant inverse relationship was observed
between lateral E:E0 and IL-6 (b=0.868, P=0.03). In contrast,
no significant associations were observed between cardiac
parameters and endothelial function, before or after incuba-
tion with NG-monomethyl-L-arginine.
Discussion
We herein report the first study to correlate small artery
structural and functional indices with target organ diastolic
impairment in patients with metabolic syndrome. Our most
important observation was that in patients with metabolic
syndrome, abnormal growth of the small artery wall was
closely associated with the degree of diastolic dysfunction. By
contrast, there was no correlation between the degree of
endothelial damage and diastolic dysfunction, even though
there was substantial impairment to the vasodilatory capacity
of the vascular endothelium in obese patients. As such, our
results lend weight to the increasingly held view that
abnormal small artery remodeling is relevant to the patho-
genesis of downstream target organ damage in obesity and
type 2 diabetes mellitus.8,19,20
The microcirculation serves several critical functions,
including autoregulation of hydrostatic pressures and control
of local and systemic peripheral vascular resistance.21,22 We
examined small arteries of between 100 and 150 lm in
lumen diameter, which form an important component of the
resistance vasculature. The small artery profile, specifically
the integrity of the myogenic response and structural changes
to the arterial wall, are both robust prognostic parameters for
subsequent target organ damage.9 Pathological alterations in
subcutaneous small artery structure associate strongly with
cardiovascular mortality,19,23 particularly outward growth of
the small artery wall.19 Obesity has a profound effect on both
the structure and function of human subcutaneous small
arteries: from a structural perspective, arteries exhibit an
outward growth pattern with hypertrophy of the wall.24,25
Inclusion of a small “control group” in our study served to
indicate the small artery phenotype of the cohort with
metabolic syndrome. This confirmed greater wall thickness in
obese individuals. Other groups have described more pro-
nounced hypertrophic changes in obesity26 and metabolic
syndrome,25 with increased wall-to-lumen ratio and cross-
sectional areas when compared with lean individuals. Detailed
assessment of structural changes in metabolic syndrome
versus health was not an aim of the current study, but
previous investigations from our group and others have
demonstrated that a number of metabolic factors contribute
to wall hypertrophy24 and that this is a dynamic process that
is reversible with effective metabolic and blood pressure
improvements.8,24 Structural changes of the arterial wall
therefore represent a spectrum of progressive change, which
are influenced by both lifestyle and drug therapy. Given the
heterogeneous nature of metabolic syndrome, there will
naturally be pathophysiological variations between different
Table 2. Small Artery Profile and Echocardiographic
Examination of Patients With Metabolic Syndrome and Control
Subjects




Endo L-NMMA 76.859.95 78.009.90 0.88




Wall thickness 24.795.06 19.904.79 0.07
LV mass 183.5143.51 152.9541.14 0.26




E:A ratio 0.930.23 1.190.17 0.048
Mean TDI E:A 0.780.30 0.880.28 0.54
Septal E:E0 11.163.72 9.632.67 0.49
Lateral E:E0 8.904.17 5.731.68 0.16
Comparison of structural characteristics of small arteries from subcutaneous gluteal fat
samples and echocardiographic assessment of diastolic parameters in patients with
metabolic syndrome and healthy control participants. Values are meanSD. CSA
indicates cross-sectional area; L-NMMA, NG-monomethyl-L-arginine; LA, left atrial; LV, left
ventricle; TDI, tissue Dopper imaging.
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cohorts, and we have therefore provided detailed character-
ization of our study group in the patient demographics.
Functionally, our ex vivo findings demonstrated reductions
in acetylcholine-induced vasodilation and thickening of the
small artery wall in the obese patients. Echocardiography in
obese participants also demonstrated lower E:A ratios
compared with healthy participants, as described previously.
Changes in the E:A ratio reflect elevated filling pressures,
which in turn reduce the filling velocity, reflecting early
diastolic disease. However, transmitral Doppler patterns such
as the E:A ratio are sensitive to preload and therefore display
a nonlinear progression in diastolic disease (“pseudonormal-
ization”). By comparison, assessment with tissue Doppler
imaging is less load dependent and as such is a more linear
and reliable measure of progressive diastolic impairment.
Here, E0 reflects the velocity of early myocardial relaxation as
the mitral annulus ascends during early rapid LV filling. Thus,
an E:E0 ratio (taking lateral annular values) <8 is normal, and
values >10 correlate with elevated LV end-diastolic pres-
sures.27
The primary aim of the study was to test the hypothesis
that increases in small artery wall thickness and wall-to-lumen
ratio are associated with impaired diastolic indices in patients
with metabolic syndrome. In this regard, the major observa-
tion from this study was that lateral E:E0 values significantly
correlated with subcutaneous small artery wall-to-lumen ratio,
even after adjustment for age and sex. The association of
diastolic dysfunction with abnormal small artery remodeling
A B
C D
Figure 2. Correlation curves for small artery measurements against echocardiographic parameters. Correlation curves illustrating
associations between (A) left atrial volume and endothelial function (r=0.210, P=0.57); (B) left atrial volume and small artery wall thickness
(r=0.718, P=0.02); and (C) left atrial volume and small artery wall:lumen ratio (r=0.605, P=0.02); (D) lateral E:E0 and wall:lumen ratio (r=0.596,
P=0.02).
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was further strengthened by significant correlations between
left atrial volume and both small artery wall thickness and the
wall-to-lumen ratio. Left atrial dilatation is invariably present
in heart failure, irrespective of ejection fraction,28 and it is
established that left atrial volume increases proportionally
with the severity of diastolic dysfunction, independent of
comorbid risks.29 As such, left atrial volume is felt to be one
of the most sensitive and specific measures to differentiate
between HFpEF and hypertensive changes to the heart.28 In
contrast, there were no significant relationships between the
endothelial-derived vasodilatory capacity of the artery and
cardiac function. Our study is small and not powered to
conclusively rule out relationships between small artery
indices where no significance is seen. However, the lack of
association between diastolic parameters and endothelial
vasodilation is consistent with existing literature.30
As a driver for progressive cardiovascular dysfunction in
obesity, inflammation is undoubtedly key.5 Specifically in
regard to HFpEF, Paulus has recently proposed that obesity-
related inflammation and subsequent overproduction of
reactive oxygen species limits local NO bioavailability within
cardiomyocytes inducing dysfunction.5 Cytokines such as
TNF-a have been reported to disrupt NO bioavailability in
obesity,31 which led us to assess systemic inflammation by
Table 3. Multiple Regression Analysis Models for Explaining the Variance of Diastolic Parameters Among Individuals With
Metabolic Syndrome
Variable b BSE P Value R2 Change
2C LA Vol
CSA 0.621 0.00020.000 0.11 0.196
Wall thickness 0.718 0.0170.006 0.02 0.377
Wall:lumen ratio 0.605 0.0140.005 0.02 0.347
Endothelial function 0.210 0.0020.004 0.57 0.040
Endo L-NMMA 0.001 0.00020.004 1.00 0.000
hsCRP 0.023 0.0010.007 0.94 0.001
TNF 0.300 0.0090.012 0.49 0.062
IL-6 0.127 0.0030.010 0.789 0.009
Lateral E:E0
CSA 0.206 0.00010.000 0.60 0.023
Wall thickness 0.495 0.0170.010 0.11 0.195
Wall:lumen ratio 0.596 0.0190.007 0.02 0.352
Endothelial function 0.088 0.0010.005 0.80 0.007
Endo L-NMMA 0.143 0.0030.005 0.59 0.017
hsCRP 0.026 0.0010.010 0.93 0.001
TNF 0.527 0.0200.012 0.12 0.239
IL-6 0.868 0.0240.009 0.03 0.429
E:A ratio
CSA 0.291 0.000010.000 0.14 0.046
Wall thickness 0.119 0.0020.003 0.48 0.011
Wall:lumen ratio 0.045 0.0010.003 0.77 0.002
Endothelial function 0.010 0.00010.002 0.96 0.000
Endo L-NMMA 0.092 0.0010.002 0.64 0.007
hsCRP 0.011 0.0000.003 0.94 0.000
TNF 0.096 0.0020.004 0.57 0.008
IL-6 0.018 0.0000.004 0.93 0.000
Multiple regression analysis is shown using left atrial volume, E:A ratio, lateral E:E0 as outcome variables and cross-sectional area, wall thickness, wall-to-lumen ratio, endothelial function,
endothelial function in presence of L-NMMA, highly sensitive CRP, TNF, and IL-6 as explanatory variables. Correlations were adjusted for age and sex. BSE represents unstandardized
coefficients (coefficients of the estimated regression model). b represents standardized coefficients. R2 represents coefficient of variations. Values are meanSD. CSA indicates cross-
sectional area; IL-6, interleukin 6; 2C LA Vol, 2-chamber left atrial volume; hsCRP, highly sensitive C-reactive protein; L-NMMA, NG-monomethyl-L-arginine; TNF, tumor necrosis factor.
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measuring circulating TNF and IL-6. Although no associations
were identified between TNF-a or high-sensitivity C-reactive
protein and any of the echo parameters, there was a
significant inverse relationship observed between lateral E:E0
and IL-6 (b=0.868, P=0.03). IL-6 exhibits complex biology:
In addition to inflammatory processes, IL-6 is widely recog-
nized for its the role in the regulation of metabolic,
regenerative, and neural processes.32 Indeed, IL-6 is released
by skeletal muscle and has well-described regenerative and
anti-inflammatory activities, working to inhibit cytokines such
as TNF-a.33 Furthermore, IL-6/ mice develop late-onset
obesity,34 glucose intolerance, and insulin resistance.35
Against this background, the inverse relationship between E:
E0 and IL-6 may provide insights into the functional pleiotropy
of IL-6 and its role in anti-inflammatory processes in skeletal
muscle.
Taken in totality, the associations observed between left
atrial volume, the E:E0 ratio, and the abnormal wall growth of
small arteries in patients with metabolic syndrome support an
association between small artery dysfunction and diastolic
heart failure. The interpretation of our results within the
hypothesis outlined above rests on an implied assumption of
small artery pathology; namely, that processes occurring in
subcutaneous small arteries mirror those in the myocardium.
As such the findings are associative, but previous studies
have shown that structural and functional changes that occur
in subcutaneous small arteries in response to hypertension
and diabetes mellitus36 are mirrored in mesenteric,37 coro-
nary,38 and cerebral39 arteries. Also, abnormal structure of
small retinal arteries in patients with type 1 diabetes mellitus
predicts not only retinopathy20 but also nephropathy,40
suggestive of a generalized microvascular burden. Although
we have presented correlation analyses in graphical form, our
adjusted logistic regression models validly describe the
association between small vessel morphology with respect
to CSA, wall thickness, wall-to-lumen ratio, and endothelial
function, with corresponding echo parameters. In the absence
of follow-up on small artery morphology at baseline and
incident changes in echo parameters over time, which is
prohibitively challenging because of repeated invasive biop-
sies required, it would not be possible to imply causation or
anything beyond an association. Although this might be
considered a limitation in study design, direct interrogation of
human arterial tissue samples provides mechanistic insights
beyond that afforded by biomarker studies, where association
is again an inherent limitation.
Patients with preclinical diastolic dysfunction and diabetes
mellitus have more than double the rates of progression to
symptomatic heart failure and mortality compared with those
without diabetes mellitus.41 From a translational perspective,
it is therefore important to examine the temporal link between
development of risk factors, functional changes to small
arteries, and myocardial dysfunction, to determine the
sequence of events that ultimately lead to symptomatic heart
failure and premature death in these patients. The data from
this study suggest that manipulation of these molecular
targets within small arteries may be relevant to the treatment
of diastolic heart failure.
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